Bulleted clinical pearls at the end of each chapter, as well as specific clinical recommendations and detailed case discussions throughout the book, make it easier for readers to retain knowledge and integrate it into their practice.
With a new foreword by Nora Volkow, Director of the National Institute on Drug Abuse, this second edition of Office-Based Buprenorphine Treatment of Opioid Use Disorder provides updated information on evidence-based treatment for opioid use disorder (OUD) -- an increasingly important topic as the epidemic of opioid misuse and overdose deaths grows in the United States.
Bulleted clinical pearls at the end of each chapter, as well as specific clinical recommendations and detailed case discussions throughout, make it easier for readers to retain knowledge and integrate it into their clinical practice. The guide also features sample documentation and scales, including a treatment contract and a patient consent, that can be used to model documents in practice.
This new edition of Office-Based Buprenorphine Treatment has been updated to reflect DSM-5 language, and two additional chapters have been included: one that addresses other pharmacotherapies useful in treating OUD, including methadone and naltrexone, and another that discusses OUD treatment specifically with regard to women's health and pregnancy.
Among the numerous other revisions included in the second edition are the following: Information about new formulations of buprenorphine A discussion of the Comprehensive Addiction and Recovery Act (CARA) Changes to induction and maintenance target doses and recommendations for home inductions Information on diversion control plans Advice for working with Alcoholics Anonymous and Narcotics Anonymous A discussion on integrating buprenorphine into residential and inpatient opioid treatment programs
This edition can also be used to complete the 8 hours of qualifying training required for the buprenorphine waiver. By a thorough reading of the material covered in the chapters of this book and successful completion of the posttest, physicians can meet the buprenorphine waiver training requirement.
Written in a jargon-free style that does not require expertise in substance use disorder treatment, Office-Based Buprenorphine Treatment of Opioid Use Disorder is an accessible, indispensable reference for primary care physicians, psychiatrists, nurse practitioners, residents, medical students, and anyone with an interest in learning about and prescribing buprenorphine.
ContributorsDedicationForewordObtaining the Buprenorphine WaiverChapter 1. Opioid Use Disorder in America: History and OverviewChapter 2. General Opioid PharmacologyChapter 3. Efficacy and Safety of BuprenorphineChapter 4. Patient AssessmentChapter 5. Clinical Use of BuprenorphineChapter 6. Buprenorphine Treatment in Office-Based SettingsChapter 7. Psychosocial and Supportive TreatmentChapter 8. Referral, Logistics, and DiversionChapter 9. Methadone, Naltrexone, and NaloxoneChapter 10. Psychiatric ComorbidityChapter 11. Medical ComorbidityChapter 12. Acute and Chronic PainChapter 13. Opioid Use by AdolescentsChapter 14. Women's Health and PregnancyChapter 15. Comments on the Case VignettesAppendix 1: Useful Web Sites and Recommended ReadingsAppendix 2: Buprenorphine and Office-Based Treatment of Opioid Use Disorder Supplemental MaterialsIndex